title: Expression of rasGTPase activating protein in basal cell carcinoma of the skin.
abstract: The ras proto-oncogene, a key component in the signal transduction cascade of activated growth factors, is involved in multiple tumor types, including basal cell carcinoma (BCC). rasGTPase activating protein (rasGAP), is a dual function protein in the ras signaling pathway, i.e., it downregulates activated ras via its catalytic domain, and it also participates in the downstream effector signaling pathway by mediating protein-protein interaction. Missense mutations presumably leading to rasGAP activation were previously detected in this gene, in a subset of BCCs. To assess the role of rasP21 and rasGAP in BCC tumorigenesis, we performed an immunohistochemical analysis of 48 BCCs, of which 45 were of the circumscribed variant (indolent-growth tumors) and the remaining 3 (2 morpheaform, 1 infiltrative), were aggressive-growth variants. rasGAP overexpression was demonstrated in 7 of 48 BCC cases, i.e., in 4 (8.8%) of 45 indolent-growth cases and in all of the 3 aggressive-growth cases. We detected tumor-specific reduction of rasP21 levels in 5 (11.1%) of 45 cases. There was no overlap between the tumors displaying rasGAP and rasP21 alternations and a high proliferation index, as assessed by Ki-67 staining, except for one case of aggressive-growth variant. We conclude that rasGAP overexpression is associated with BCC tumorigenesis in a ras-independent manner, is not reflective of the proliferation status of the tumor, and is more characteristic of aggressive-growth BCCs.
authors.affiliation: Department of Pathology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: I
authors.initials: I
authors.lastname: Barshack
authors.forename: I
authors.initials: I
authors.lastname: Goldberg
authors.forename: B
authors.initials: B
authors.lastname: Davidson
authors.forename: A
authors.initials: A
authors.lastname: Ravid
authors.forename: G
authors.initials: G
authors.lastname: Schiby
authors.forename: J
authors.initials: J
authors.lastname: Kopolovic
authors.forename: A
authors.initials: A
authors.lastname: Leviav
authors.forename: E
authors.initials: E
authors.lastname: Friedman
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis / Q000096:biosynthesis; D002280:Basal Cell Carcinoma / Q000737:chemistry* / Q000378:metabolism / Q000473:pathology; D004817:Epidermis / Q000737:chemistry / Q000378:metabolism; D020558:GTP Phosphohydrolases / Q000032:analysis / Q000096:biosynthesis; D020690:GTPase-Activating Proteins; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis / Q000096:biosynthesis; D014176:Protein Biosynthesis; D011506:Proteins / Q000032:analysis*; D000090063:Proto-Oncogene Mas; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis / Q000096:biosynthesis; D012878:Skin Neoplasms / Q000737:chemistry* / Q000378:metabolism / Q000473:pathology; D020703:ras GTPase-Activating Proteins
chemical_list: D014408:Biomarkers, Tumor; D020690:GTPase-Activating Proteins; D019394:Ki-67 Antigen; C000715470:MAS1 protein, human; D011506:Proteins; D000090063:Proto-Oncogene Mas; D020703:ras GTPase-Activating Proteins; D020558:GTP Phosphohydrolases; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)